CORAL GABLES, FL / ACCESSWIRE / March 8, 2019 / The healthcare stock market has seen impressive gains in the first few months of 2019 as we've seen several major shifts to the healthcare system in the U.S. In the last few years, by virtue of technological advancements and cultural changes, the healthcare industry has become increasingly more patient-centered. Until recently, patients were less vocal about their needs and the privacy of their medical records, but, just like consumers advocating for better customer experience, so, too, are patients expecting quality from their care providers. If companies in the healthcare sector continue to rise to the growing challenges presented by new diseases, patient expectations, and the ever-changing political climate, investors looking for potential opportunities could benefit from keeping healthcare on their radar. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Seelos Therapeutics Inc (SEEL), Bio-Path Holdings Inc (NASDAQ:BPTH), and TrovaGene Inc (NASDAQ:TROV) are 4 healthcare companies with a clean bill of health on Friday.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.
In recognition of future applications of new technologies for healthcare, Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced that it will be working with NexTech AR solutions to explore bringing augmented reality technology to its patient-centric healthcare app. Premier Health will be working with NexTech to develop educational tools for healthcare professionals and patients alike - some of which will be created and commercialized content for third parties. Through the use of AR as a learning tool in training healthcare professionals, this will create a highly engaging and immersive educational experience which aids in retention and how well complex concepts can be grasped.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), commented, "at Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient-centric telemedicine app. AR has the potential to revolutionize both the access to data and the delivery of healthcare."
Seelos Therapeutics Inc (SEEL), a clinical-stage biopharmaceutical company, announced earlier this week that it has acquired an exclusive license to intellectual property owned by The Regents of the University of California pertaining to a technology that was created by researchers at the University of California, Los Angeles. Per the details of the announcement, such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein).
Raj Mehra, Founder, and CEO of Seelos said, "accumulation and aggregation of α-synuclein is a pathological hallmark of PD. Though its role is not completely understood, it appears pivotal in the pathogenesis of PD and other α-synucleinopathies such as dementia with Lewy bodies and multiple system atrophy."
Bio-Path Holdings Inc (BPTH) saw its shares enjoy an astounding 223.19% boost late in yesterday's trading, with its shares closing out the day at $38.86 per share. Several analysts believe the momentum gained resulted from The Company's detailing their most recent clinical update to the previously reported interim analysis from the Phase 2 trial of prexibersen (BP1001) for the treatment of acute myeloid leukemia.
Following the announcement, Peter Nielsen, President, and CEO of Bio-Path said, "we were particularly pleased with these results, especially when you consider that the large percentage of these patients are secondary AML patients. The CR/CRp/CRi rate for LDAC treatment alone for the class of patients in this study was benchmarked at 7-13%, whereas prexigebersen treatment with LDAC is currently showing a 29% CR/CRi/MLFS rate, with a highly favorable safety profile."
TrovaGene Inc (TROV), a clinical-stage oncology therapeutics company, announced earlier this week company highlights and financial results for the fourth quarter and full-year ended December 31, 2018.
Dr. Thomas Adams, Chief Executive Officer and Chairman of Trovagene, commented, "we are pleased with the progress we are making in the clinical development of onvansertib for the treatment of cancers and indications where there is a significant need to bring new therapeutic options to physicians and their patients - Acute Myeloid Leukemia, metastatic Castration-Resistant Prostate Cancer and Metastatic Colorectal Cancer."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: